DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Covestor Ltd

Covestor Ltd raised its position in DexCom, Inc. (NASDAQ:DXCM) by 53.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 959 shares of the medical device company’s stock after buying an additional 335 shares during the period. Covestor Ltd’s holdings in DexCom were worth $64,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the 2nd quarter worth approximately $25,000. Sachetta LLC raised its position in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom during the 1st quarter valued at approximately $29,000. Riverview Trust Co raised its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. Finally, DT Investment Partners LLC raised its position in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after buying an additional 315 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wells Fargo & Company lifted their price target on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Oppenheimer cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group reissued a “buy” rating and issued a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Sanford C. Bernstein boosted their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, Morgan Stanley dropped their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Trading Up 3.0 %

NASDAQ DXCM opened at $74.68 on Friday. The stock has a market capitalization of $29.17 billion, a P/E ratio of 43.29, a P/E/G ratio of 2.28 and a beta of 1.17. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a 50-day moving average price of $69.77 and a 200 day moving average price of $92.14. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.